) recently announced that it has launched over-the-counter (OTC)
nicotine polacrilex mini lozenge, 2 mg (mint flavor) and 4 mg
(mint flavor). We note that the product was approved by the US
Food and Drug Administration (FDA) in Oct 2012 for reducing
withdrawal symptoms like nicotine craving, associated with
This is the first marketed mini lozenge product targeting the
store brand market. The mint flavored mini lozenge can be
) Nicorette mini lozenge. Perrigo stated in its press release
that annual sales of Nicorette mini lozenge are more than $30
million at all retail outlets.
We remind investors that earlier this month, Perrigo announced
the launch of betamethasone valerate foam 0.12%. It is the
generic equivalent of Stiefel Laboratories' Luxiq foam. Stiefel
is a GlaxoSmithKline company.
We note that the product was approved in the US in Nov 2012
for the relief of corticosteroid-responsive skin conditions of
the scalp or scalp psoriasis. The offering had annual branded
sales of about $40 million.
We believe that Perrigo's dominant position in the store brand
OTC drug market has further strengthened recent approvals. The
company's strong position in the brand OTC pharmaceutical market
and growing generics and active pharmaceuticals ingredient
businesses are expected to drive growth in the coming
Perrigo, an S&P 500 stock, carries a Zacks Rank #3 (Hold)
in the short run. S&P 500 companies that currently look
Eli Lilly and Company
). Both Zacks Rank #2 (Buy) stocks are expected to perform well
in the coming quarters.
GLAXOSMITHKLINE (GSK): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
PERRIGO COMPANY (PRGO): Free Stock Analysis
To read this article on Zacks.com click here.